Elevated hypermutation levels in HIV-1 natural viral suppressors

Virology

Volumn 443, Issue 2, 2013, Pages 306-312

  Eyzaguirre, Lindsay M ^a,b   Charurat, Manhattan ^a,b   Redfield, Robert R ^a,b   Blattner, William A ^a,b   Carr, Jean K ^a,b,c   Sajadi, Mohammad M ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Alabama College of Osteopathic Medicine ^*  (United States)

^c Alabama College of Osteopathic Medicine   (United States)

Author keywords

Elite controllers; HIV 1; Hypermutation; Natural viral suppressors (NVS)

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; NEF PROTEIN; VIRUS DNA;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERMUTATION; IMMUNITY; MALE; MUTATION; MUTATION RATE; MUTATIONAL ANALYSIS; NATURAL VIRAL SUPPRESSOR; NEF GENE; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; START CODON; VIRUS GENOME; VIRUS INACTIVATION; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84880510054     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.05.019     Document Type: Article

References (57)

1. Arroyo M.A., Hoelscher M., Sanders-Buell E., Herbinger K.H., Samky E., Maboko L., Hoffmann O., Robb M.R., Birx D.L., McCutchan F.E. HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania. AIDS Res. Hum. Retroviruses 2004, 20:895-901.
2. *57-positive patient during virologic escape. J. Infect. Dis. 2007, 196:50-55.
3. Baker B.M., Block B.L., Rothchild A.C., Walker B.D. Elite control of HIV infection: implications for vaccine design. Expert Opin. Biol. Ther. 2009, 9:55-69.
4. Blankson J.N. Control of HIV-1 replication in elite suppressors. Discov. Med. 2010, 9:261-266.
5. Blankson J.N., Bailey J.R., Thayil S., Yang H.C., Lassen K., Lai J., Gandhi S.K., Siliciano J.D., Williams T.M., Siliciano R.F. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J. Virol. 2007, 81:2508-2518.
6. Brumme Z.L., Li C., Miura T., Sela J., Rosato P.C., Brumme C.J., Markle T.J., Martin E., Block B.L., Trocha A., Kadie C.M., Allen T.M., Pereyra F., Heckerman D., Walker B.D., Brockman M.A. Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J. Acquir. Immune. Defic. Syndr. 2011, 56:100-108.
7. Buzon M.J., Seiss K., Weiss R., Brass A.L., Rosenberg E.S., Pereyra F., Yu X.G., Lichterfeld M. Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J. Virol. 2011, 85:9646-9650.
8. Caly L., Saksena N.K., Piller S.C., Jans D.A. Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor. Retrovirology 2008, 5:67.
9. Carr J.K., Salminen M.O., Koch C., Gotte D., Artenstein A.W., Hegerich P.A., Louis D., Burke D.S., McCutchan F.E. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J. Virol. 1996, 70:5935-5943.
10. Carr J.K., Torimiro J.N., Wolfe N.D., Eitel M.N., Kim B., Sanders-Buell E., Jagodzinski L.L., Gotte D., Burke D.S., Birx D.L., McCutchan F.E. The AG recombinant IbNG and novel strains of group M HIV-1 are common in Cameroon. Virology 2001, 286:168-181.
11. Deeks S.G., Barre-Sinoussi F. Public health: towards a cure for HIV. Nature 2012, 487:293-294.
12. Edo-Matas D., van Gils M.J., Bowles E.J., Navis M., Rachinger A., Boeser-Nunnink B., Stewart-Jones G.B., Kootstra N.A., van 't Wout A.B., Schuitemaker H. Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 2010, 405:492-504.
13. Gandhi S.K., Siliciano J.D., Bailey J.R., Siliciano R.F., Blankson J.N. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J. Virol. 2008, 82:3125-3130.
14. Goulder P.J., Brander C., Tang Y., Tremblay C., Colbert R.A., Addo M.M., Rosenberg E.S., Nguyen T., Allen R., Trocha A., Altfeld M., He S., Bunce M., Funkhouser R., Pelton S.I., Burchett S.K., McIntosh K., Korber B.T., Walker B.D. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412:334-338.
15. Grabar S., Selinger-Leneman H., Abgrall S., Pialoux G., Weiss L., Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009, 23:1163-1169.
16. Graf E.H., Mexas A.M., Yu J.J., Shaheen F., Liszewski M.K., Di Mascio M., Migueles S.A., Connors M., O'Doherty U. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+patients on and off HAART. PLoS Pathog. 2011, 7:e1001300.
17. Harris R.S., Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 2004, 4:868-877.
18. Hatano H., Delwart E.L., Norris P.J., Lee T.H., Dunn-Williams J., Hunt P.W., Hoh R., Stramer S.L., Linnen J.M., McCune J.M., Martin J.N., Busch M.P., Deeks S.G. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J. Virol. 2009, 83:329-335.
19. Holmes R.K., Koning F.A., Bishop K.N., Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 2007, 282:2587-2595.
20. Hunt P.W. Natural control of HIV-1 replication and long-term nonprogression: overlapping but distinct phenotypes. J. Infect. Dis. 2009, 200:1636-1638.
21. Iversen A.K., Shpaer E.G., Rodrigo A.G., Hirsch M.S., Walker B.D., Sheppard H.W., Merigan T.C., Mullins J.I. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J. Virol. 1995, 69:5743-5753.
22. Judo M.S., Wedel A.B., Wilson C. Stimulation and suppression of PCR-mediated recombination. Nucleic Acids Res. 1998, 26:1819-1825.
23. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., Wei X., Jiang C., Kirchherr J.L., Gao F., Anderson J.A., Ping L.H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., Shaw G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Nat. Acad. Sci. U.S.A. 2008, 105:7552-7557.
24. Kumar S., Tamura K., Nei M. MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 2004, 5:150-163.
25. Lecossier D., Bouchonnet F., Clavel F., Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003, 300:1112.
26. Linton, E.W., MacGDE 2.4: Genetic Data Environment for MacOS X, 2.4 ed.
27. Liu B., Sarkis P.T., Luo K., Yu Y., Yu X.F. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 2005, 79:9579-9587.
28. Liu T.F., Shafer R.W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin. Infect. Dis. 2006, 42:1608-1618.
29. Lole K.S., Bollinger R.C., Paranjape R.S., Gadkari D., Kulkarni S.S., Novak N.G., Ingersoll R., Sheppard H.W., Ray S.C. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J. Virol. 1999, 73:152-160.
30. Lum J.J., Cohen O.J., Nie Z., Weaver J.G., Gomez T.S., Yao X.J., Lynch D., Pilon A.A., Hawley N., Kim J.E., Chen Z., Montpetit M., Sanchez-Dardon J., Cohen E.A., Badley A.D. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J. Clin. Invest. 2003, 111:1547-1554.
31. Malim M.H., McCarn D.F., Tiley L.S., Cullen B.R. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J. Virol. 1991, 65:4248-4254.
32. Mens H., Kearney M., Wiegand A., Shao W., Schonning K., Gerstoft J., Obel N., Maldarelli F., Mellors J.W., Benfield T., Coffin J.M. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J. Virol. 2010, 84:12971-12981.
33. Meyerhans A., Vartanian J.P., Wain-Hobson S. DNA recombination during PCR. Nucleic Acids Res. 1990, 18:1687-1691.
34. *5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Nat. Acad. Sci. U.S.A. 2000, 97:2709-2714.
35. Mologni D., Citterio P., Menzaghi B., Zanone Poma B., Riva C., Broggini V., Sinicco A., Milazzo L., Adorni F., Rusconi S., Galli M., Riva A. Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. AIDS 2006, 20:567-574.
36. O'Connell K.A., Brennan T.P., Bailey J.R., Ray S.C., Siliciano R.F., Blankson J.N. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J. Virol. 2010, 84:7018-7028.
37. Okulicz J.F., Marconi V.C., Landrum M.L., Wegner S., Weintrob A., Ganesan A., Hale B., Crum-Cianflone N., Delmar J., Barthel V., Quinnan G., Agan B.K., Dolan M.J. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J. Infect. Dis. 2009, 200:1714-1723.
38. Pace C., Keller J., Nolan D., James I., Gaudieri S., Moore C., Mallal S. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 2006, 80:9259-9269.
39. Pauza C.D. Two bases are deleted from the termini of HIV-1 linear DNA during integrative recombination. Virology 1990, 179:886-889.
40. Poropatich K., Sullivan D.J. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J. Gen. Virol. 2011, 92:247-268.
41. Rhee S.Y., Gonzales M.J., Kantor R., Betts B.J., Ravela J., Shafer R.W. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003, 31:298-303.
42. Rose P.P., Korber B.T. Detecting hypermutations in viral sequences with an emphasis on G-> A hypermutation. Bioinformatics 2000, 16:400-401.
43. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987, 4:406-425.
44. Sajadi M.M., Heredia A., Le N., Constantine N.T., Redfield R.R. HIV-1 natural viral suppressors: control of viral replication in the absence of therapy. AIDS 2007, 21:517-519.
45. Sajadi M.M., Constantine N.T., Mann D.L., Charurat M., Dadzan E., Kadlecik P., Redfield R.R. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J. Acquir. Immune. Defic. Syndr. 2009, 50:403-408.
46. Salazar-Gonzalez J.F., Bailes E., Pham K.T., Salazar M.G., Guffey M.B., Keele B.F., Derdeyn C.A., Farmer P., Hunter E., Allen S., Manigart O., Mulenga J., Anderson J.A., Swanstrom R., Haynes B.F., Athreya G.S., Korber B.T., Sharp P.M., Shaw G.M., Hahn B.H. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 2008, 82:3952-3970.
47. Salazar-Gonzalez J.F., Salazar M.G., Learn G.H., Fouda G.G., Kang H.H., Mahlokozera T., Wilks A.B., Lovingood R.V., Stacey A., Kalilani L., Meshnick S.R., Borrow P., Montefiori D.C., Denny T.N., Letvin N.L., Shaw G.M., Hahn B.H., Permar S.R. Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J. Virol. 2011, 85:2751-2763.
48. *57 positive elite suppressors. Retrovirology 2010, 7:94.
49. Salminen M.O., Carr J.K., Burke D.S., McCutchan F.E. Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res. Hum. Retroviruses 1995, 11:1423-1425.
50. Sandonis V., Casado C., Alvaro T., Pernas M., Olivares I., Garcia S., Rodriguez C., del Romero J., Lopez-Galindez C. A combination of defective DNA and protective host factors are found in a set of HIV-1 ancestral LTNPs. Virology 2009, 391:73-82.
51. Shafer R.W. Rationale and uses of a public HIV drug-resistance database. J. Infect. Dis. 2006, 194(1):S51-58.
52. Simmonds P., Balfe P., Ludlam C.A., Bishop J.O., Brown A.J. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J. Virol. 1990, 64:5840-5850.
53. Simmonds P., Balfe P., Peutherer J.F., Ludlam C.A., Bishop J.O., Brown A.J. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J. Virol. 1990, 64:864-872.
54. Tolstrup M., Laursen A.L., Gerstoft J., Pedersen F.S., Ostergaard L., Duch M. Cysteine 138 mutation in HIV-1 Nef from patients with delayed disease progression. Sex. Health 2006, 3:281-286.
55. Walker B.D. Elite control of HIV infection: implications for vaccines and treatment. Top. HIV Med. 2007, 15:134-136.
56. Wang B., Mikhail M., Dyer W.B., Zaunders J.J., Kelleher A.D., Saksena N.K. First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology 2003, 312:135-150.
57. Whitcomb J.M., Kumar R., Hughes S.H. Sequence of the circle junction of human immunodeficiency virus type 1: implications for reverse transcription and integration. J. Virol. 1990, 64:4903-4906.